
-
Vertex Pharmaceuticals Incorporated NasdaqGS:VRTX Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Location: 50 Northern Avenue, Boston, MA, 02210, United States | Website: https://www.vrtx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
110.3B
Cash
6.201B
Avg Qtr Burn
-245.1M
Short % of Float
1.88%
Insider Ownership
0.16%
Institutional Own.
97.88%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
JOURNAVX™ (suzetrigine) (VX-548) Details Pain, Acute pain | Approved Quarterly sales | |
ORKAMBI® (lumacaftor/ivacaftor) Details Cystic fibrosis | Approved Quarterly sales | |
Approved Quarterly sales | ||
CASGEVY™ (exagamglogene autotemcel) (exa-cel) (CTX001) Details Sickle cell disease | Approved Quarterly sales | |
Approved Quarterly sales | ||
KALYDECO® (ivacaftor) Details Cystic fibrosis | Approved Quarterly sales | |
CASGEVY™ (exagamglogene autotemcel) (exa-cel) (CTX001) Details Beta thalessemia | Approved Quarterly sales | |
KALYDECO® (ivacaftor) Details Cystic fibrosis | Approved Quarterly sales | |
SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) Details Cystic fibrosis (CF) | Approved Quarterly sales | |
Approved Quarterly sales | ||
Povetacicept Details IgA Nephropathy (IgAN) | Phase 3 Data readout | |
JOURNAVX™ (suzetrigine) (VX-548) Details Pain, Diabetic peripheral neuropathy | Phase 3 Data readout | |
Inaxaplin (VX-147) Details APOL1-Mediated Kidney Disease (AMKD) | Phase 3 Data readout | |
VX-993 Details Diabetic peripheral neuropathy (DPN) | Phase 2 Data readout | |
VX-993 Details Moderate-to-severe acute pain following bunionectomy surgery | Phase 2 Data readout | |
JOURNAVX™ (suzetrigine) (VX-548) Details Pain, Lumbosacral radiculopathy | Phase 2 Update | |
VX-407 Details Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 Initiation | |
Povetacicept Details IgA nephropathy, primary membranous nephropathy (pMN) | Phase 1/2 Data readout | |
VX-522 Details Cystic fibrosis | Phase 1/2 Update | |
Zimislecel (VX-880) Details Type 1 diabetes | Phase 1/2 Update | |
VX-993 (IV formulation) Details Healthy volunteers | Phase 1 Update | |
VX-264 Details Type 1 diabetes | Failed Discontinued | |
VX-864 Details Severe alpha-1 antitrypsin deficiency | Failed Discontinued |